Company news
Jcr Pharmaceuticals Co., Ltd. (TSE:4552) news
Every Jcr Pharmaceuticals Co., Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
FY2026 First Quarter Results Briefing Session Material
July 30, 2026
JCR Pharmaceuticals - Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation
July 23, 2026
Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation
July 22, 2026
JCR Pharmaceuticals Announces Development Plan in Japan for Givinostat for Duchenne Muscular Dystrophy
July 14, 2026
Matters Concerning Controlling Shareholders (Affiliated Companies)
June 23, 2026
JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders
February 4, 2026
JCR Pharmaceuticals : FY2025 Third Quarter Results Briefing Session - Script（1,742KB）
January 30, 2026
JCR Pharmaceuticals : FY2025-Q3 Financial Report (Oct. 1-Dec. 31, 2025)（390KB）
January 28, 2026
JCR Pharmaceuticals to Present at the 22nd Annual WORLDSymposium™ 2026
January 27, 2026
JCR Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in Rare Disease
December 24, 2025
JCR Pharmaceuticals : FY2025 Second Quarter Results Briefing Session - Script（1,455KB）
November 4, 2025
JCR Pharmaceuticals : FY2025-Q2 Financial Report (Jul. 1-Sep. 30, 2025)（536KB）
October 30, 2025
JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology
October 7, 2025
JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets
October 1, 2025
JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
September 30, 2025
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of Japan
September 29, 2025
JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program
September 19, 2025
JCR Pharmaceuticals Celebrates its 50th Anniversary of Advancing Science and Changing Lives
September 12, 2025
JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025
September 8, 2025
MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis
September 2, 2025
JCR Pharmaceuticals to Present at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) 2025
August 28, 2025
JCR Pharmaceuticals : FY2025-Q1 Financial Report (Apr. 1-Jun. 30, 2025)（340KB）
July 30, 2025
JCR Pharmaceuticals Selected for Japan’s Regenerative Medicine CDMO Subsidy Program
July 16, 2025
JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
July 15, 2025
JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines
July 8, 2025
JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical Trial
July 2, 2025
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by European Commission (EC)
June 24, 2025
JCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS) Type II Disease Awareness Film Featured in The Next Frontier Series
June 18, 2025
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
June 6, 2025
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising CNS Uptake at American Society of Gene and Cell Therapy 28th Annual Meeting
May 16, 2025
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA
May 7, 2025